AlphaCentric Advisors’s Biogen BIIB Stock Holding History

AlphaCentric Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$841K	Buy	3,891 +56	+1%	+$10.7K	0.71%	36
2026 Q1	$703K	Buy	3,835 +208	+6%	+$38.3K	0.7%	35
2025 Q4	$638K	Buy	+3,627	New	+$593K	0.64%	44
2021 Q4	–	Sell	-400	Closed	-$113K	–	226
2021 Q3	$113K	Hold	400	–	–	0.03%	155
2021 Q2	$139K	Hold	400	–	–	0.04%	147
2021 Q1	$112K	Hold	400	–	–	0.04%	138
2020 Q4	$98K	Buy	400 +370	+1,233%	+$95.5K	0.04%	136
2020 Q3	$9K	Sell	30 -90	-75%	-$25.1K	﹤0.01%	158
2020 Q2	$32K	Buy	+120	New	+$36.1K	0.02%	103

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AlphaCentric Advisors's BIIB Position: Q2 2026 in Review

AlphaCentric Advisors increased its Biogen (BIIB) stake by 1.5% in Q2 2026, buying an estimated $10.7K and bringing the position to 3,891 shares worth $841K. The position accounts for 0.71% of the portfolio, ranked #36.

AlphaCentric Advisors first reported a position in BIIB in Q2 2020 and has held it in 9 quarters since. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

AlphaCentric Advisors held 3,891 shares of Biogen worth $841K as of Q2 2026.
AlphaCentric Advisors bought 56 Biogen shares in Q2 2026, an estimated $10.7K.
Biogen made up 0.71% of AlphaCentric Advisors's portfolio in Q2 2026, its #36 holding.
AlphaCentric Advisors first reported a position in Biogen in Q2 2020 and has held it in 9 quarters since.
1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.